AUPH

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in Victoria, Canada. The company went public in 2014 and has evolved from a research-focused biotech into a commercial enterprise following the approval of its lead drug LUPKYNIS in 2021. Aurinia specializes in developing therapies for autoimmune diseases with significant unmet medical needs, particularly focusing on lupus nephritis, a severe kidney complication affecting lupus patients. The company has successfully transitioned from a loss-making development-stage company to profitability, generating over $235 million in revenue in 2024.